Keros Therapeutics (KROS) Gets a Hold from William Blair
Protect Your Portfolio Against Market Uncertainty
Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
According to TipRanks, Phipps is an analyst with an average return of -10.3% and a 35.07% success rate. Phipps covers the Healthcare sector, focusing on stocks such as Incyte, Bristol-Myers Squibb, and Amgen.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Keros Therapeutics with a $30.71 average price target.
Based on Keros Therapeutics' latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $3.04 million and a GAAP net loss of $46.03 million. In comparison, last year the company earned a revenue of $143 thousand and had a GAAP net loss of $40.24 million
Based on the recent corporate insider activity of 7 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of KROS in relation to earlier this year. Last month, ADAR1 Capital Management, LLC, a Major Shareholder at KROS bought 934,258.00 shares for a total of $9,462,055.64.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
William Blair Maintained a Hold Rating on Clarivate Plc (CLVT)
Clarivate Plc (NYSE:CLVT) is one of the . On July 31, William Blair analyst Andrew Nicholas maintained a Hold rating on Clarivate Plc (NYSE:CLVT) without disclosing any price target. The analyst noted that the company's second-quarter results were strong, and the revenue and EPS exceeded expectations. This growth was driven by strong performance in key areas including academia, government, life sciences, and healthcare. However, despite this performance, the stock price dropped after the release, mainly due to a lack of major news on the company's strategic review, as investors were expecting clearer updates. A state-of-the-art computer lab filled with engineers working on new analytics technologies. Moreover, Nicholas also highlighted some upsides and risks for the company, including a slight increase in recurring revenue and some segments returning to growth. However, Clarivate Plc (NYSE:CLVT) faces risks from academic and government sector budget cuts and less US federal spending. Clarivate Plc (NYSE:CLVT) provides data, analytics, and workflow solutions to help organizations make informed decisions. It serves sectors like academia, government, intellectual property, and life sciences. While we acknowledge the potential of CLVT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
2 days ago
- Yahoo
Alnylam's Amvuttra Makes Powerful Entrance, Eyes First-Line Dominance
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) reported upbeat second-quarter earnings and 2025 guidance on Thursday. The company reported a second-quarter 2025 adjusted earnings of 32 cents, down from 56 cents a year ago. Analysts estimated a loss of 79 cents. The company reported quarterly sales of $773.69 million, up 17% year over year, beating the consensus of $638.55 Pharmaceuticals achieved global net product revenues for Amvuttra and Onpattro for the second quarter of $492 million and $53 million. The company achieved global net product revenues for Givlaari and Oxlumo for the second quarter of $81 million and $47 million. Alnylam raised its fiscal 2025 sales guidance from $2.7 billion-$3 billion to $3.3 billion-$3.55 billion compared to the consensus of $2.89 billion. Chardan Research and William Blair have both issued positive outlooks on Alnylam following the second-quarter results. Chardan Research stated that the launch of Amvuttra for ATTR-CM (Transthyretin Amyloid Cardiomyopathy) is off to an exceptionally strong start. ATTR-CM, or transthyretin amyloid cardiomyopathy, is a rare and often underdiagnosed form of heart failure. The company achieved approximately 1,400 ATTR-CM Patients on Amvuttra (vutrisiran) as of June 30, 2025, resulting in an approximately $150 million step-up in revenue. View more earnings on ALNY In March, the U.S. Food and Drug Administration on Thursday approved Amvuttra (vutrisiran) in adults with cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis, or ATTR-CM. Chardan analyst Keay Nakae on Thursday wrote, 'We believe this speaks volumes about management confidence in the near-term launch progression. Commercially we believe that the totality of the data leaves Amvuttra well positioned to achieve significant market share as 1st line therapy.' Chardan reiterated the Buy rating, while raising the price forecast from $325 to $400. William Blair on Thursday wrote, 'We believe that Alnylam is the premier siRNA therapeutics company, and with the P5x25 corporate strategy intact, the company is on track to achieve profitability by the end of 2025 and become a fully sustainable biotech growth story.' Various analysts have reacted positively to Alnylam's performance, with several firms reiterating or maintaining their Buy or Overweight ratings and significantly raising their price forecasts. Morgan Stanley maintained an Equal-Weight rating, increasing its price forecast from $312 to $405. Piper Sandler and Barclays both maintained Overweight ratings, with Piper Sandler raising its forecast from $304 to $449, and Barclays increasing its target from $329 to $460. Raymond James reiterated an Outperform rating, boosting its price forecast from $370 to $424. Wells Fargo maintained an Equal-Weight rating, raising its price forecast from $333 to $395. Canaccord Genuity held a Buy rating, raising its forecast from $390 to $415, while UBS also maintained a Buy rating, notably increasing its price forecast from $403 to $550. Price Action: ALNY stock is trading higher by 1.56% to $398.36 at last check Friday. Read Next:Photo via Shutterstock Latest Ratings for ALNY Date Firm Action From To Mar 2022 Citigroup Initiates Coverage On Buy Feb 2022 Morgan Stanley Maintains Overweight Feb 2022 SVB Leerink Maintains Market Perform View More Analyst Ratings for ALNY View the Latest Analyst Ratings Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? ALNYLAM PHARMACEUTICALS (ALNY): Free Stock Analysis Report This article Alnylam's Amvuttra Makes Powerful Entrance, Eyes First-Line Dominance originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
CNBC
5 days ago
- CNBC
Wall Street sees Starbucks comeback taking hold, even after another lackluster quarter
Wall Street is seeing early signs that Starbucks' turnaround is taking hold, despite a quarterly earnings miss and another quarter of shrinking same-store sales. "The focus for Starbucks' third fiscal quarter was less on the results (which were below Street expectations) and more on proof points on the pace of the potential recovery ahead," William Blair analyst Sharon Zackfia wrote in a note to clients Wednesday. The company reported weaker-than-expected earnings for its fiscal third quarter on Tuesday evening. Its same-store sales fell for the sixth straight quarter, but executives told analysts on the company's earnings call that traffic improved sequentially every month of the quarter. Another promising sign came in traffic growth from non-Starbucks Rewards members. For several years, the number of Starbucks customers who don't belong to its loyalty program has fallen, making the cohort the primary culprit for the chain's recent sluggish sales. RBC Capital Markets analyst Logan Reich entitled his Wednesday research note about the company's results "green shoots getting greener." He pointed to CEO Brian Niccol's comments that the turnaround is ahead of schedule, the accelerated rollout of its new "Green Apron Service" labor program and mobile app changes, among other factors. The labor changes aim to create a more welcoming environment in cafes while ensuring fast service. Starbucks also teased new menu items coming in fiscal 2026, including protein cold foam and improved food options. T.D. Cowen analyst Andrew Charles wrote in a research note on Wednesday that he has greater confidence that Starbucks' same-store sales will continue to improve due to the company's "more aggressive innovation agenda." But while many analysts presented a bullish case for the company's turnaround, not all investors are sold on Niccol and his "Back to Starbucks" strategy. The comeback is taking longer than originally anticipated, based on Wall Street's expectations of when the company's same-store sales will grow again. Shares of Starbucks fell more than 1% in morning trading on Wednesday, after climbing as much as 5% in extended trading following the results. The stock has slid about 1% this year, giving it a market cap of about $104 billion.
